Pfizer-BioNTech vaccine in patients undergoing cancer treatment

What The Study Did:

T

he SARS-CoV-2 BNT162b2 (Pfizer-BioNTech) vaccine


appeared to be safe and achieve satisfactory serologic status in patients with cancer. While there


was a lag in antibody production compared with the rate in the noncancer control group


,


seroconversion occurred in most patients after the second dose.

Authors:


Irit


Ben-Aharon, M.D., Ph.D., of the


Rambam Health Care


Campus in Haifa


, Israel


,


is the

corresponding author.

To access the embargoed study:

Visit our For The Media website at this link

https:/

/

media.

jamanetwork.

com/

(doi:10.1001/jamaoncol.2021.2675)

Editor’s Note:

The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

###

Media advisory:

The full article is linked to this news release.

Embed this link to provide your readers free access to the full-text article

This link will be live at the embargo time

https:/

/

jamanetwork.

com/

journals/

jamaoncology/

fullarticle/

10.

1001/

jamaoncol.

2021.

2675?guestAccessKey=

a006b52c-6abf-414d-b0b9-b57946450d20&utm_source=

For_The_Media&utm_medium=

referral&utm_campaign=

ftm_links&utm_content=

tfl&utm_term=

070821